Cover Image
市場調查報告書

專業蛋白轉換酵素Subtilisin/Kexin9型 (PCSK9) :開發中產品分析

Proprotein Convertase Subtilisin/Kexin Type 9 (Proprotein Convertase 9 or Neural Apoptosis Regulated Convertase 1 or Subtilisin/Kexin Like Protease PC9 or PCSK9 or EC 3.4.21.) - Pipeline Review, H2 2017

出版商 Global Markets Direct 商品編碼 363582
出版日期 內容資訊 英文 95 Pages
訂單完成後即時交付
價格
Back to Top
專業蛋白轉換酵素Subtilisin/Kexin9型 (PCSK9) :開發中產品分析 Proprotein Convertase Subtilisin/Kexin Type 9 (Proprotein Convertase 9 or Neural Apoptosis Regulated Convertase 1 or Subtilisin/Kexin Like Protease PC9 or PCSK9 or EC 3.4.21.) - Pipeline Review, H2 2017
出版日期: 2017年10月10日 內容資訊: 英文 95 Pages
簡介

本報告提供專業蛋白轉換酵素Subtilisin/Kexin9型 (PCSK9)的開發情形相關的資訊,各開發階段、藥物標的、作用機制、給藥途徑及各分子類型的分析,開發治療藥的企業概要,最新消息和新聞稿等資訊,為您概述為以下內容。

簡介

  • 調查範圍

專業蛋白轉換酵素Subtilisin/Kexin9型 (PCSK9)的概要

治療藥的開發

專業蛋白轉換酵素Subtilisin/Kexin9型 (PCSK9):開發中的產品 - 各開發階段

專業蛋白轉換酵素Subtilisin/Kexin9型 (PCSK9):開發中的產品 - 各治療範圍

專業蛋白轉換酵素Subtilisin/Kexin9型 (PCSK9):開發中的產品 - 各適應症

專業蛋白轉換酵素Subtilisin/Kexin9型 (PCSK9):開發中產品概況

  • 後期階段的產品
  • 初期階段的產品
  • 開發階段不明的產品

專業蛋白轉換酵素Subtilisin/Kexin9型 (PCSK9):企業開發中的產品

專業蛋白轉換酵素Subtilisin/Kexin9型 (PCSK9):大學/機關開發中的產品

專業蛋白轉換酵素Subtilisin/Kexin9型 (PCSK9):治療藥的評估

  • 各單劑療法/聯合治療產品
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

專業蛋白轉換酵素Subtilisin/Kexin9型 (PCSK9)的治療藥的開發企業

  • Abeome Corporation
  • AFFiRiS AG
  • Alnylam Pharmaceuticals, Inc.
  • Amgen Inc.
  • Betagenon AB
  • BioLingus AG
  • Catabasis Pharmaceuticals, Inc.
  • 第一三共
  • Eli Lilly and Company
  • HitGen LTD
  • 興和
  • Kymab Limited
  • MedImmune, LLC
  • Merck & Co., Inc.
  • Pfizer Inc.
  • Planet Biotechnology Inc.
  • Regeneron Pharmaceuticals, Inc.
  • Serometrix, LLC
  • Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.
  • Thetis Pharmaceuticals LLC

藥物簡介

專業蛋白轉換酵素Subtilisin/Kexin9型 (PCSK9):暫停中的計劃

專業蛋白轉換酵素Subtilisin/Kexin9型 (PCSK9):開發中止的產品

專業蛋白轉換酵素Subtilisin/Kexin9型 (PCSK9):主要消息與新聞稿

附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC1038TDB

Summary:

Proprotein Convertase Subtilisin/Kexin Type 9 (Proprotein Convertase 9 or Neural Apoptosis Regulated Convertase 1 or Subtilisin/Kexin Like Protease PC9 or PCSK9 or EC 3.4.21.) pipeline Target constitutes close to 28 molecules. Out of which approximately 26 molecules are developed by companies and remaining by the universities/institutes. The latest report Proprotein Convertase SubtilisinKexin Type 9 - Pipeline Review, H2 2017, outlays comprehensive information on the Proprotein Convertase Subtilisin/Kexin Type 9 (Proprotein Convertase 9 or Neural Apoptosis Regulated Convertase 1 or Subtilisin/Kexin Like Protease PC9 or PCSK9 or EC 3.4.21.) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

Proprotein Convertase Subtilisin/Kexin Type 9 (Proprotein Convertase 9 or Neural Apoptosis Regulated Convertase 1 or Subtilisin/Kexin Like Protease PC9 or PCSK9 or EC 3.4.21.) - Proprotein convertase subtilisin/kexin type 9 (PCSK9) is an enzyme encoded by the PCSK9 gene. It is a crucial player in the regulation of plasma cholesterol homeostasis. It binds to low-density lipid receptor family members. It acts via a non-proteolytic mechanism to enhance the degradation of the hepatic LDLR through a clathrin LDLRAP1/ARH-mediated pathway. It prevents the recycling of LDLR from endosomes to the cell surface or directs it to lysosomes for degradation. It induces ubiquitination of LDLR leading to its subsequent degradation. It inhibits intracellular degradation of APOB via the autophagosome/lysosome pathway in a LDLR-independent manner. The molecules developed by companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 1, 3, 4, 3, 8, 6 and 1 respectively. Similarly, the universities portfolio in Preclinical and Discovery stages comprises 1 and 1 molecules, respectively. Report covers products from therapy areas Metabolic Disorders, Cardiovascular, Gastrointestinal, Immunology, Infectious Disease and Oncology which include indications Hypercholesterolemia, Hyperlipidemia, Atherosclerosis, Cardiovascular Disease, Homozygous Familial Hypercholesterolemia (HoFH), Non-Alcoholic Steatohepatitis (NASH), Type 2 Diabetes, Bacterial Sepsis, Hypertriglyceridemia, Inflammation, Liver Diseases, Metabolic Syndrome, Non Alcoholic Fatty Liver Disease (NAFLD) and Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD).

Furthermore, this report also reviews key players involved in Proprotein Convertase Subtilisin/Kexin Type 9 (Proprotein Convertase 9 or Neural Apoptosis Regulated Convertase 1 or Subtilisin/Kexin Like Protease PC9 or PCSK9 or EC 3.4.21.) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The report provides a snapshot of the global therapeutic landscape for Proprotein Convertase Subtilisin/Kexin Type 9 (Proprotein Convertase 9 or Neural Apoptosis Regulated Convertase 1 or Subtilisin/Kexin Like Protease PC9 or PCSK9 or EC 3.4.21.)
  • The report reviews Proprotein Convertase Subtilisin/Kexin Type 9 (Proprotein Convertase 9 or Neural Apoptosis Regulated Convertase 1 or Subtilisin/Kexin Like Protease PC9 or PCSK9 or EC 3.4.21.) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Proprotein Convertase Subtilisin/Kexin Type 9 (Proprotein Convertase 9 or Neural Apoptosis Regulated Convertase 1 or Subtilisin/Kexin Like Protease PC9 or PCSK9 or EC 3.4.21.) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Proprotein Convertase Subtilisin/Kexin Type 9 (Proprotein Convertase 9 or Neural Apoptosis Regulated Convertase 1 or Subtilisin/Kexin Like Protease PC9 or PCSK9 or EC 3.4.21.) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Proprotein Convertase Subtilisin/Kexin Type 9 (Proprotein Convertase 9 or Neural Apoptosis Regulated Convertase 1 or Subtilisin/Kexin Like Protease PC9 or PCSK9 or EC 3.4.21.) targeted therapeutics

Reasons to buy:

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Proprotein Convertase Subtilisin/Kexin Type 9 (Proprotein Convertase 9 or Neural Apoptosis Regulated Convertase 1 or Subtilisin/Kexin Like Protease PC9 or PCSK9 or EC 3.4.21.)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Proprotein Convertase Subtilisin/Kexin Type 9 (Proprotein Convertase 9 or Neural Apoptosis Regulated Convertase 1 or Subtilisin/Kexin Like Protease PC9 or PCSK9 or EC 3.4.21.) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Proprotein Convertase Subtilisin/Kexin Type 9 (Proprotein Convertase 9 or Neural Apoptosis Regulated Convertase 1 or Subtilisin/Kexin Like Protease PC9 or PCSK9 or EC 3.4.21.) - Overview
    • Proprotein Convertase Subtilisin/Kexin Type 9 (Proprotein Convertase 9 or Neural Apoptosis Regulated Convertase 1 or Subtilisin/Kexin Like Protease PC9 or PCSK9 or EC 3.4.21.) - Therapeutics Development
    • Products under Development by Stage of Development
    • Products under Development by Therapy Area
    • Products under Development by Indication
    • Products under Development by Companies
    • Products under Development by Universities/Institutes
  • Proprotein Convertase Subtilisin/Kexin Type 9 (Proprotein Convertase 9 or Neural Apoptosis Regulated Convertase 1 or Subtilisin/Kexin Like Protease PC9 or PCSK9 or EC 3.4.21.) - Therapeutics Assessment
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Proprotein Convertase Subtilisin/Kexin Type 9 (Proprotein Convertase 9 or Neural Apoptosis Regulated Convertase 1 or Subtilisin/Kexin Like Protease PC9 or PCSK9 or EC 3.4.21.) - Companies Involved in Therapeutics Development
    • AFFiRiS AG
    • Betagenon AB
    • Bioleaders Corp
    • BioLingus AG
    • Catabasis Pharmaceuticals Inc
    • Dicerna Pharmaceuticals Inc
    • Eli Lilly and Co
    • Ensemble Therapeutics Corp
    • Kowa Co Ltd
    • Novartis AG
    • Pfizer Inc
    • Regeneron Pharmaceuticals Inc
    • Serometrix LLC
    • Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd
    • The Medicines Company
  • Proprotein Convertase Subtilisin/Kexin Type 9 (Proprotein Convertase 9 or Neural Apoptosis Regulated Convertase 1 or Subtilisin/Kexin Like Protease PC9 or PCSK9 or EC 3.4.21.) - Drug Profiles
    • AK-102 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • alirocumab - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Antisense Oligonucleotide to Inhibit PCSK9 for Hypercholesterolemia - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Antisense RNAi Oligonucleotide to Inhibit PCSK-9 for Hypercholesterolemia - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • AT-04A - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • AT-06A - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • BLSM-201 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • CAT-2000 Series - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • CVI-LM001 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • DCRPCSK-9 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Gene Therapy to Inhibit PCSK9 for Hypercholesterolemia - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • inclisiran - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • JS-002 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • K-312 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • lodelcizumab - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • LY-3015014 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Monoclonal Antibodies to Inhibit PCSK9 for Hypercholesterolemia - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Monoclonal Antibody to Inhibit PCSK9 for Hypercholesterolemia - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • O-304 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • PF-06446846 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Recombinant Protein to Inhibit PCSK9 for Hypercholesterolemia - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule to Inhibit PCSK9 for Hypercholesterolemia - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule to Inhibit PCSK9 for Hypercholesterolemia - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Inhibit PCSK9 for Cardiovascular Disease - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Inhibit PCSK9 for Hypercholesterolemia - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • SX-PCK9 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Synthetic Peptide to Inhibit PCSK9 for Hypercholesterolemia - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Vaccine to Target PCSK9 for Hypercholesterolemia - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Proprotein Convertase Subtilisin/Kexin Type 9 (Proprotein Convertase 9 or Neural Apoptosis Regulated Convertase 1 or Subtilisin/Kexin Like Protease PC9 or PCSK9 or EC 3.4.21.) - Dormant Products
  • Proprotein Convertase Subtilisin/Kexin Type 9 (Proprotein Convertase 9 or Neural Apoptosis Regulated Convertase 1 or Subtilisin/Kexin Like Protease PC9 or PCSK9 or EC 3.4.21.) - Discontinued Products
  • Proprotein Convertase Subtilisin/Kexin Type 9 (Proprotein Convertase 9 or Neural Apoptosis Regulated Convertase 1 or Subtilisin/Kexin Like Protease PC9 or PCSK9 or EC 3.4.21.) - Product Development Milestones
    • Featured News & Press Releases
      • Aug 28, 2017: New, One-Year Data from ORION-1 Phase II Study of Inclisiran Extends Excellent Long-Term Efficacy and Safety Profile, Affirming Dose for Phase III Trials
      • Aug 25, 2017: Regeneron and Sanofi to Present New Analyses from Praluent Injection Trials at the ESC Congress 2017
      • Jun 11, 2017: Medication That Inhibits PCSK9 Safely Reduces Cardiovascular Risk in Patients with Type 2 Diabetes
      • Jun 11, 2017: Sanofi and Regeneron Announce Positive Results from First Dedicated Studies Evaluating Praluent (alirocumab) in Individuals with Diabetes and Hypercholesterolemia
      • Apr 26, 2017: The Medicines Company and Alnylam Pharmaceuticals Announce Agreement with FDA on Phase III Clinical Program for Inclisiran
      • Apr 25, 2017: Regeneron And Sanofi Announce FDA Approval Of A New Once-Monthly Dosing Option For Praluent (Alirocumab) Injection
      • Mar 17, 2017: The Medicines Company and Alnylam Pharmaceuticals Report Positive Final Results from ORION-1 Phase II Study of Inclisiran
      • Mar 14, 2017: The Medicines Company to Webcast Presentation of ORION-1 Phase II Study of Inclisiran at ACC.17
      • Mar 07, 2017: Regeneron and Sanofi to Present New Phase 3 Praluent (alirocumab) Injection Clinical Trial Analyses at ACC.17 Scientific Sessions
      • Feb 08, 2017: Appeals Court Grants Stay of Permanent Injunction for Praluent (alirocumab) During Appeals Process
      • Jan 25, 2017: The Medicines Company to Present Results from ORION-1 Phase 2 Study of Inclisiran at the American College of Cardiology's 66th Annual Scientific Session
      • Jan 13, 2017: Sanofi and Regeneron File Notice of Appeal and Motion to Stay (Suspend) Injunction with Federal Circuit Court of Appeals in Patent Case Regarding Praluent (alirocumab) Injection
      • Jan 09, 2017: Amgen Statement on January 9, 2017, U.S. District Court Decision
      • Jan 08, 2017: The Medicines Company Announces Positive Top-Line Results from Day 180 Interim Analysis in Ongoing ORION-1 Phase 2 Study of Inclisiran
      • Jan 05, 2017: Regeneron and Sanofi to Appeal U.S. District Court Rulings in Ongoing Patent Litigation Regarding Praluent (alirocumab) Injection
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
  • Disclaimer

List of Tables

  • Number of Products under Development by Stage of Development, H2 2017
  • Number of Products under Development by Therapy Areas, H2 2017
  • Number of Products under Development by Indication, H2 2017
  • Number of Products under Development by Companies, H2 2017
  • Number of Products under Development by Companies, H2 2017 (Contd..1)
  • Products under Development by Companies, H2 2017
  • Products under Development by Companies, H2 2017 (Contd..1), H2 2017
  • Products under Development by Companies, H2 2017 (Contd..2), H2 2017
  • Number of Products under Investigation by Universities/Institutes, H2 2017
  • Products under Investigation by Universities/Institutes, H2 2017
  • Number of Products by Stage and Mechanism of Actions, H2 2017
  • Number of Products by Stage and Route of Administration, H2 2017
  • Number of Products by Stage and Molecule Type, H2 2017
  • Pipeline by AFFiRiS AG, H2 2017
  • Pipeline by Betagenon AB, H2 2017
  • Pipeline by Bioleaders Corp, H2 2017
  • Pipeline by BioLingus AG, H2 2017
  • Pipeline by Catabasis Pharmaceuticals Inc, H2 2017
  • Pipeline by Dicerna Pharmaceuticals Inc, H2 2017
  • Pipeline by Eli Lilly and Co, H2 2017
  • Pipeline by Ensemble Therapeutics Corp, H2 2017
  • Pipeline by Kowa Co Ltd, H2 2017
  • Pipeline by Novartis AG, H2 2017
  • Pipeline by Pfizer Inc, H2 2017
  • Pipeline by Regeneron Pharmaceuticals Inc, H2 2017
  • Pipeline by Serometrix LLC, H2 2017
  • Pipeline by Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd, H2 2017
  • Pipeline by The Medicines Company, H2 2017
  • Dormant Products, H2 2017
  • Dormant Products, H2 2017 (Contd..1), H2 2017
  • Discontinued Products, H2 2017

List of Figures

  • Number of Products under Development by Stage of Development, H2 2017
  • Number of Products under Development by Therapy Areas, H2 2017
  • Number of Products under Development by Top 10 Indications, H2 2017
  • Number of Products by Stage and Mechanism of Actions, H2 2017
  • Number of Products by Routes of Administration, H2 2017
  • Number of Products by Stage and Routes of Administration, H2 2017
  • Number of Products by Molecule Types, H2 2017
  • Number of Products by Stage and Molecule Types, H2 2017
Back to Top